Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118356 | 1.00 | PTPRC (0.57) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL27713616 | 0.98 | PTPRC (0.55) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| Anthracene SCHEMBL27939488 | 0.98 | PTPRC (0.55) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| Methane SCHEMBL27586780 | 0.98 | PTPRC (0.55) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL29415866 | 0.98 | PTPRC (0.55) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL29391697 | 0.96 | PTPRC (0.53) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL27552426 | 0.96 | PTPRC (0.53) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL30337382 | 0.96 | PTPRC (0.53) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL146910 | 0.96 | PTPRC (0.53) | PTPRCALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL448680 | 0.96 | PTPRC (0.53) | PTPRCALDH1A1HPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2564 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-12625142-B2 | Assay for measuring binding affinity for cardiolipin of biologically active compounds | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2026-05-12 | — | — | US | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4639646-A1 | A SODIUM, LITHIUM OR POTASSIUM AQUEOUS BATTERY, AND A METHOD OF MANUFACTURING SUCH A BATTERY | Technische Universiteit Delft (NL) | 2025-10-29 | — | — | EP | claimed |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| US-20250177303-A1 | A DRUG NANOCARRIER SYSTEM TO DELIVER A COMBINATION OF TLR AGONISTS AND/OR A LIPOXIN PLUS IMMUNOGENIC CELL DEATH INDUCING CHEMOTHERAPEUTIC AGENTS FOR CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025080869-A1 | PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| US-11464879-B2 | Cellular targeted active ingredient delivery system | CELLIS AG | 2022-10-11 | — | — | US | claimed |
| US-20220280663-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | CELLIS AG (CH) | 2022-09-08 | — | — | US | claimed |
| EP-4045054-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | The Regents of the University of California (US) | 2022-08-24 | — | — | EP | claimed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114727967-A | Nucleic acid mediated delivery of therapeutic agents | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | claimed |
| WO-2022087371-A1 | NOVEL BICYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| CN-114207050-A | Composite particles comprising a hydrophobic dye and an amphiphilic block copolymer and their use in optical applications | 史密斯实验室公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022034464-A1 | GROUND COVER MATERIALS | NINE IP LIMITED (NZ) | 2022-02-17 | — | — | WO | claimed |